See more : Hamamatsu Photonics K.K. (6965.T) Income Statement Analysis – Financial Results
Complete financial analysis of ImmunityBio, Inc. (IBRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmunityBio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- YFY Inc. (1907.TW) Income Statement Analysis – Financial Results
- Kohoku Kogyo CO.,LTD. (6524.T) Income Statement Analysis – Financial Results
- Muzhu Mining Ltd. (MUZU.CN) Income Statement Analysis – Financial Results
- Vario Secure Inc. (4494.T) Income Statement Analysis – Financial Results
- Amazonas Florestal, Ltd (AZFL) Income Statement Analysis – Financial Results
ImmunityBio, Inc. (IBRX)
About ImmunityBio, Inc.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 622.00K | 240.00K | 934.00K | 605.00K | 2.20M | 47.00K | 45.00K | 44.00K | 236.00K | 641.00K | 600.00K |
| Cost of Revenue | 0.00 | 24.19M | 0.00 | 9.15M | 9.01M | -3.11M | 0.00 | 0.00 | 0.00 | 0.00 | 253.00K |
| Gross Profit | 622.00K | -23.95M | 934.00K | -8.54M | -6.81M | 3.16M | 45.00K | 44.00K | 236.00K | 641.00K | 347.00K |
| Gross Profit Ratio | 100.00% | -9,980.00% | 100.00% | -1,411.90% | -309.26% | 6,717.02% | 100.00% | 100.00% | 100.00% | 100.00% | 57.83% |
| Research & Development | 232.37M | 248.15M | 195.96M | 139.51M | 112.00M | 53.42M | 39.78M | 26.55M | 11.43M | 1.60M | 446.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.39M | 57.12M | 95.39M | 227.68M | 4.33M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.07M | -3.30M | -1.00M | -1.47M | 0.00 | 0.00 |
| SG&A | 129.62M | 102.71M | 135.26M | 71.32M | 46.46M | 35.46M | 53.82M | 94.39M | 226.21M | 4.33M | 2.42M |
| Other Expenses | 886.00K | -736.00K | 193.00K | 1.49M | -534.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 362.87M | 350.86M | 331.21M | 210.83M | 158.45M | 88.88M | 93.60M | 120.94M | 237.64M | 5.92M | 2.87M |
| Cost & Expenses | 362.87M | 350.86M | 331.21M | 210.83M | 158.45M | 98.44M | 99.17M | 124.54M | 239.11M | 6.24M | 2.87M |
| Interest Income | 863.00K | 2.71M | 836.00K | 1.73M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K |
| Interest Expense | 129.20M | 63.52M | 14.85M | 9.07M | 5.92M | 433.00K | 618.00K | 66.00K | 0.00 | 0.00 | 463.00K |
| Depreciation & Amortization | 18.51M | 24.19M | 19.12M | 9.15M | 9.01M | 9.56M | 5.57M | 3.61M | 1.47M | 128.00K | 4.00K |
| EBITDA | -436.18M | -335.51M | -315.38M | -187.93M | -142.27M | -86.74M | -90.73M | -117.71M | -235.71M | -5.68M | -1.58M |
| EBITDA Ratio | -70,125.72% | -143,324.17% | -33,865.52% | -32,252.56% | -6,356.77% | -189,008.51% | -207,897.78% | -274,756.82% | -100,594.92% | -949.14% | -263.17% |
| Operating Income | -362.25M | -351.30M | -330.28M | -220.88M | -156.25M | -98.39M | -99.12M | -124.50M | -238.88M | -6.21M | -2.27M |
| Operating Income Ratio | -58,239.55% | -146,374.17% | -35,361.88% | -36,509.09% | -7,095.87% | -209,338.30% | -220,266.67% | -282,954.55% | -101,218.64% | -969.11% | -378.17% |
| Total Other Income/Expenses | -221.64M | -65.99M | -19.56M | -25.36M | -3.95M | 1.66M | 2.20M | 3.12M | 1.70M | -609.00K | 223.00K |
| Income Before Tax | -583.89M | -417.29M | -349.84M | -226.03M | -160.26M | -96.73M | -96.92M | -121.38M | -237.18M | -6.21M | -2.05M |
| Income Before Tax Ratio | -93,873.31% | -173,869.17% | -37,456.00% | -37,360.83% | -7,278.07% | -205,806.38% | -215,368.89% | -275,865.91% | -100,498.73% | -969.11% | -341.00% |
| Income Tax Expense | -40.00K | 34.00K | 9.00K | -1.85M | -105.00K | -503.00K | -493.00K | -572.00K | -301.00K | 1.00K | 1.00K |
| Net Income | -583.20M | -417.32M | -349.85M | -224.19M | -160.16M | -96.23M | -96.42M | -120.81M | -236.88M | -6.21M | -2.05M |
| Net Income Ratio | -93,761.41% | -173,883.33% | -37,456.96% | -37,055.70% | -7,273.30% | -204,736.17% | -214,273.33% | -274,565.91% | -100,371.19% | -969.27% | -341.17% |
| EPS | -1.15 | -1.04 | -0.90 | -0.59 | -0.42 | -1.22 | -1.20 | -1.47 | -3.31 | -0.02 | -2.57 |
| EPS Diluted | -1.15 | -1.04 | -0.90 | -0.59 | -0.42 | -1.22 | -1.20 | -1.47 | -3.31 | -0.02 | -2.57 |
| Weighted Avg Shares Out | 508.64M | 399.90M | 389.23M | 383.18M | 383.18M | 79.13M | 80.58M | 81.98M | 71.52M | 315.73M | 797.11K |
| Weighted Avg Shares Out (Dil) | 508.64M | 399.90M | 389.23M | 383.18M | 383.18M | 79.13M | 80.58M | 81.98M | 71.52M | 315.73M | 797.11K |
ImmunityBio: Moving The Needle
ImmunityBio's ANKTIVA shows promising commercial and clinical progress, with expanded patient access and potential EU/UK regulatory filings, enhancing its global market penetration and revenue prospects. Recent positive clinical data for ANKTIVA in NSCLC and endometrial cancer trials highlight its potential...
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt
Anktiva, ImmunityBio's lead molecule, shows promising results with a 71% CR rate and 100% survival at 24 months for BCG-unresponsive NMIBC. Despite Anktiva's potential, ImmunityBio faces financial challenges, relying heavily on loans from founder Dr. Soon-Shiong, leading to high indebtedness....
Top 3 Health Care Stocks That Are Set To Fly This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'
ImmunityBio received FDA approval for ANKTIVA plus BCG for BCG-unresponsive bladder cancer in April. The drug has a unique mechanism of action. Immunity's early launch progress of Anktiva shows promising market access initiatives, but financial concerns remain due to high...
ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.28 per share a year ago.
Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm
NEW YORK , July 25, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ImmunityBio, Inc. (NASDAQ: IBRX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
7 Biotech Stocks to Keep on Your Clinical Radar
Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions...
3 Top Cancer Treatment Stocks to Buy Now
Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck's (NYSE: MRK ) Keytruda, generated $25 billion in revenue for the pharmaceutical giant last year.
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the initial treatment of multiple patients in the United States to receive therapy with ANKTIVA® (nogapendekin alfa inbakicept-pmln), ImmunityBio's recently approved immunotherapy for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC)...
Source: https://incomestatements.info
Category: Stock Reports